Related Experiment Video
Updated: May 6, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
[The effectiveness of lamotrigine in a case of ring chromosome 14 with refractory epilepsy]
Kazunori Ogawa1, Kuniaki Iyoda
1Department of Child Neurology, Hiroshima City Hospital Hiroshima. ogawa4363@mtb.biglobe.ne.jp
Insights
A child with mosaic ring chromosome 14 experienced intractable seizures and developmental delay. Treatment with lamotrigine effectively controlled seizures, highlighting the importance of genetic analysis in pediatric epilepsy.
Area of Science:
- Genetics
- Neurology
- Pediatrics
Background:
- Chromosomal abnormalities can manifest as neurological disorders in children.
- Early identification and genetic analysis are crucial for diagnosing complex pediatric conditions.
Observation:
- A 25-month-old boy presented with intractable seizures and developmental retardation starting at six months of age.
- Electroencephalograms (EEGs) showed focal spikes and fast activity in the right occipital region.
- Chromosome analysis revealed a mosaic ring chromosome 14 and monosomy 14.
Findings:
- The patient exhibited refractory partial seizures, developmental delay, and acquired microcephaly, consistent with ring chromosome 14 characteristics.
- Despite no MRI abnormalities or congenital malformations, genetic analysis identified a chromosomal abnormality.
- Add-on therapy with a low dose of lamotrigine completely suppressed refractory seizures.
Implications:
- This case underscores the significance of chromosomal analysis in pediatric patients with unexplained developmental delay and refractory epilepsy.
- Lamotrigine demonstrates efficacy in managing seizures associated with ring chromosome 14.
- Further research is needed to establish consistent clinical characteristics of ring chromosome 14.
Abstract:
A 25-month old boy was admitted to our hospital due to intractable seizures and developmental retardation. At birth, the patient's head circumference was within normal limits and development appeared normal until approximately six months of age, when symptoms of mental and motor retardation, and microcephaly, gradually appeared. From three months of age, refractory complex partial seizures, secondary generalization of partial seizures, and convulsive status epilepticus occurred. Electroencephalograms (EEGs) taken prior to the patient's referral to our hospital displayed focal spikes at the right occipital region, and at 25 months of age, EEGs showed focal fast activity in the same region. Abnormalities were not detected in the patient's MRI and there was no congenital malformation. Chromosome analysis (G-banding) revealed 46, XY, r (14) (p13q32.3) [28]/45, XY, -14 [2], mosaic ring chromosome 14, and monosomy 14. Clinical experience has shown that even in the absence of malformations, children with developmental delay and refractory seizures may have chromosomal abnormalities, and this was true for our patient. Although consistent clinical characteristics of ring chromosome 14 have not yet been described, the refractory partial seizures that began in early infancy, and the gradual appearance of developmental delay with acquired microcephaly exhibited by our patient are characteristic. However, the patient's refractory seizures have been completely suppressed through an add-on therapy consisting of a relatively low dose of lamotrigine (0.7 mg/kg/day), despite the likely aggravating effect of topiramate.
More Related Videos
09:32Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
09:29Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
Related Concept Videos
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...